This study explored the potential therapeutic role of salvigenin in glucocorticoid-induced osteonecrosis of the femoral head (GIOFH), focusing on its effects on oxidative stress, osteoblast viability, and osteogenic differentiation via the estrogen receptor alpha (ESR1)-mediated pathway. Here, ESR1 is linked to osteonecrosis.